{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:27:41Z","timestamp":1789007261062,"version":"build-2803163510"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":11,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jtct.2026.02.001","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:35:59Z","timestamp":1770482159000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Breaking Access Barriers to Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy in Hematologic Malignancies\u2014an ASTCT-NMDP ACCESS Initiative"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8079-9443","authenticated-orcid":false,"given":"Pashna N.","family":"Munshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taha","family":"Al-Juhaishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1522-8924","authenticated-orcid":false,"given":"Eneida R.","family":"Nemecek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9767-9739","authenticated-orcid":false,"given":"Brenda M.","family":"Sandmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella M.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1515-2141","authenticated-orcid":false,"given":"Jeffery J.","family":"Auletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Holter","family":"Chakrabarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.02.001_bib0001","first-page":"275","article-title":"Increasing access to allotransplants in the United States: the impact of race, geography, and socioeconomics","author":"Hong","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program. 2021"},{"key":"10.1016\/j.jtct.2026.02.001_bib0002","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-019-0205-9","article-title":"Current status of autologous stem cell transplantation for multiple myeloma","volume":"9","author":"Al Hamed","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2026.02.001_bib0003","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3324\/haematol.2020.262360","article-title":"Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial","volume":". 107","author":"Pawlyn","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2026.02.001_bib0004","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use of and trends in hematopoietic cell transplantation in the United States","volume":"26","author":"D'Souza","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.02.001_bib0005","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.02.001_bib0006","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.02.001_bib0007","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2026.02.001_bib0008","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2026.02.001_bib0009","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.02.001_bib0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.02.001_bib0011","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2026.02.001_bib0012","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2026.02.001_bib0013","article-title":"Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial","volume":"29","author":"Houot","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2026.02.001_bib0014","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.bbmt.2015.03.020","article-title":"National survey of hematopoietic cell transplantation center personnel, infrastructure, and models of care delivery","volume":"21","author":"Majhail","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.02.001_bib0015","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1188\/13.CJON.405-411","article-title":"Barriers to accessing health care for hematopoietic cell transplantation recipients living in rural areas: perspectives from healthcare providers","volume":"17","author":"Moore","year":"2013","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.jtct.2026.02.001_bib0016","article-title":"Proceedings from the reimagining caregiver workshop: addressing caregiver requirements for hematopoietic cell transplant","volume":"31","author":"Preussler","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.02.001_bib0017","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.bbmt.2009.12.529","article-title":"Access to hematopoietic cell transplantation in the United States","volume":"16","author":"Majhail","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.02.001_bib0018","article-title":"Minority health and health disparities: definitions, parameters","year":"2024","journal-title":"NIMHD Research Framework"},{"key":"10.1016\/j.jtct.2026.02.001_bib0019","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.bbmt.2015.04.017","article-title":"Population-based analysis of hematologic malignancy referrals to a comprehensive cancer center, referrals for blood and marrow transplantation, and participation in clinical trial, survey, and biospecimen research by race","volume":"21","author":"Clay","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.02.001_bib0020","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1182\/bloodadvances.2024014171","article-title":"Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network","volume":"9","author":"Battiwalla","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.02.001_bib0021","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/bloodadvances.2024015013","article-title":"Receiving CAR T-cells gets faster, but not for all in need","volume":"9","author":"Ramos","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.02.001_bib0022","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/blood.2020006252","article-title":"Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis","volume":"137","author":"Bona","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.02.001_bib0023","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/cncr.33232","article-title":"Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States","volume":"127","author":"Hong","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2026.02.001_bib0024","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.bbmt.2017.02.019","article-title":"Investigating the Association of Genetic Admixture and Donor\/Recipient Genetic Disparity with Transplant Outcomes","volume":"23","author":"Madbouly","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.02.001_bib0025","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/s41409-019-0748-1","article-title":"Transplant center characteristics and survival after allogeneic hematopoietic cell transplantation in adults","volume":"55","author":"Majhail","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.02.001_bib0026","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.bbmt.2016.03.019","article-title":"Association of distance from transplantation center and place of residence on outcomes after allogeneic hematopoietic cell transplantation","volume":"22","author":"Khera","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.02.001_bib0027","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.bbmt.2016.03.008","article-title":"Time to insurance approval in private and public payers does not influence survival in patients who undergo hematopoietic cell transplantation","volume":"22","author":"Bhatt","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.02.001_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2024.09.010","article-title":"Racial and ethnic disparities in autologous hematopoietic cell transplantation utilization in multiple myeloma have persisted over time even after referral to a transplant center","volume":"30","author":"Wu","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.02.001_bib0029","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1002\/cncr.30747","article-title":"Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: a CIBMTR report","volume":"123","author":"Schriber","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2026.02.001_bib0030","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.bbmt.2009.11.007","article-title":"Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma","volume":"16","author":"Hari","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.02.001_bib0031","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.33145","article-title":"Use of hematopoietic cell transplant for hematologic cancers by race, ethnicity, and age","volume":"7","author":"Hahn","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtct.2026.02.001_bib0032","unstructured":"Guzman G. Household income by race and Hispanic origin: 2005\u20132009 and 2015\u20132019. US Census Bureau American Community Survey Brief ACSBR-7. 2020. Available at: https:\/\/www.census.gov\/content\/dam\/Census\/library\/publications\/2020\/acs\/acsbr19-07.pdf. Accessed January 1, 2026."},{"key":"10.1016\/j.jtct.2026.02.001_bib0033","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41416-020-01038-6","article-title":"Cancer health disparities in racial\/ethnic minorities in the United States","volume":"124","author":"Zavala","year":"2021","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtct.2026.02.001_bib0034","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2017.74.2049","article-title":"Racial and ethnic disparities in cancer survival: the contribution of tumor, sociodemographic, institutional, and neighborhood characteristics","volume":"36","author":"Ellis","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.02.001_bib0035","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1182\/bloodadvances.2023012469","article-title":"Trends in volumes and survival after hematopoietic cell transplantation in racial\/ethnic minorities","volume":"8","author":"Khera","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.02.001_bib0036","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.bbmt.2014.12.024","article-title":"Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma","volume":"21","author":"Costa","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.02.001_bib0037","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/cncr.29160","article-title":"Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: a single center study","volume":"121","author":"Bhatnagar","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2026.02.001_bib0038","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/ajh.23753","article-title":"Use of autologous hematopoietic cell transplantation as initial therapy in multiple myeloma and the impact of socio-geo-demographic factors in the era of novel agents","volume":"89","author":"Al-Hamadani","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2026.02.001_bib0039","doi-asserted-by":"crossref","first-page":"7330","DOI":"10.1002\/cam4.4249","article-title":"Racial and ethnic differences in the utilization of autologous transplantation for lymphoma in the United States","volume":"10","author":"Vaughn","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.jtct.2026.02.001_bib0040","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1002\/cncr.25297","article-title":"Access to hematopoietic stem cell transplantation: effect of race and sex","volume":"116","author":"Joshua","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2026.02.001_bib0041","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1002\/cncr.33831","article-title":"Outcomes of upfront autologous hematopoietic cell transplantation in patients with multiple myeloma who are 75 years old or older","volume":"127","author":"Munshi","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2026.02.001_bib0042","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jamaoncol.2025.1127","article-title":"Barriers to chimeric antigen receptor T-cell therapy","volume":"11","author":"Valtis","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtct.2026.02.001_bib0043","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009349","article-title":"Association of age, race, and ethnicity with access, response, and toxicities from CAR-T therapy in children and adults with B-cell malignancies: a review","volume":"13","author":"Ghilardi","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"e228161","key":"10.1016\/j.jtct.2026.02.001_bib0044","article-title":"Enrollment of black participants in pivotal clinical trials supporting US Food and Drug Administration approval of chimeric antigen receptor-T cell therapy for hematological malignant neoplasms","volume":"5","author":"Al Hadidi","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.001_bib0045","doi-asserted-by":"crossref","DOI":"10.1007\/s11899-024-00747-6","article-title":"Disparities in clinical trial enrollment- focus on CAR-T and bispecific antibody therapies","volume":"20","author":"Islam","year":"2024","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.jtct.2026.02.001_bib0046","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jtct.2024.10.014","article-title":"Representativeness of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) trial participants","volume":"31","author":"Kaur","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.02.001_bib0047","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.02.001_bib0048","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2026.02.001_bib0049","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2026.02.001_bib0050","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1182\/blood.2023023447","article-title":"Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity","volume":"143","author":"Locke","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.02.001_bib0051","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3109\/10428194.2012.708751","article-title":"Examining racial differences in diffuse large B-cell lymphoma presentation and survival","volume":"54","author":"Flowers","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2026.02.001_bib0052","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/cncr.33894","article-title":"Social determinants of health and cancer mortality in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study","volume":"128","author":"Pinheiro","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2026.02.001_bib0053","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s40266-023-01047-z","article-title":"Age is no barrier: CAR-T therapy in older adults","volume":"40","author":"Maakaron","year":"2023","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jtct.2026.02.001_bib0054","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jtct.2023.03.012","article-title":"Safety and efficacy of BCMA CAR-T cell therapy in older patients with multiple myeloma","volume":"29","author":"Reyes","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.02.001_bib0055","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-120013","article-title":"Safety of axicabtagene ciloleucel CD19 CAR T-cell therapy in elderly patients with relapsed or refractory large B-cell lymphoma","volume":"132","author":"Sano","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.02.001_bib0056","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3324\/haematol.2021.278288","article-title":"Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients \u2014 a matched control multicenter cohort study","volume":"107","author":"Ram","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2026.02.001_bib0057","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41409-022-01867-4","article-title":"Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA\/DRST experience","volume":"58","author":"Dreger","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"EVIDoa2300213","key":"10.1016\/j.jtct.2026.02.001_bib0058","article-title":"CAR T-cell immunotherapy in minority patients with lymphoma","volume":"3","author":"Ghilardi","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jtct.2026.02.001_bib0059","article-title":"Access and outcomes of racial and ethnic minority populations receiving commercial anti-BCMA CART for myeloma","author":"Paruzzo","year":"2025","journal-title":"Blood ICT"},{"key":"10.1016\/j.jtct.2026.02.001_bib0060","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/bloodadvances.2021005482","article-title":"Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials","volume":"6","author":"Kanapuru","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.02.001_bib0061","unstructured":"National Academies of Sciences, Engineering, and Medicine. Using Population Descriptors in Genetics and Genomics Research: A New Framework for an Evolving Field. Washington, DC: National Academies Press; 2023."},{"issue":"120","key":"10.1016\/j.jtct.2026.02.001_bib0062","article-title":"Racial disparities in multiple myeloma and access to stem cell transplantation","volume":"14","author":"Cook","year":"2024","journal-title":"Blood Cancer J"},{"issue":"86","key":"10.1016\/j.jtct.2026.02.001_bib0063","article-title":"Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities","volume":"14","author":"Ailawadhi","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2026.02.001_bib0064","unstructured":"AMN Healthcare\u2019s 2025 Survey of Physician Appointment Wait Times and Medicare and Medicaid Acceptance Rates, 2025. Available at:https:\/\/www.amnhealthcare.com\/siteassets\/amn-insights\/physician\/ps-2025-physician-appt-wait-times---wp-v6.pdf. Accessed March 17, 2026."},{"key":"10.1016\/j.jtct.2026.02.001_bib0065","unstructured":"Agency for Healthcare Research and Quality. 2017 National Healthcare Quality and Disparities Report [Internet]. Rockville (MD); 2018. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK579743\/. Accessed March 17, 2026."},{"key":"10.1016\/j.jtct.2026.02.001_bib0066","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1016\/S2352-3026(22)00360-X","article-title":"Upfront autologous transplantation still improving outcomes in patients with multiple myeloma","volume":"10","author":"Beksac","year":"2023","journal-title":"The Lancet Haematology"},{"key":"10.1016\/j.jtct.2026.02.001_bib0067","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jtct.2022.03.019","article-title":"ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma","volume":"28","author":"Dhakal","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.02.001_bib0068","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1634\/theoncologist.2017-0499","article-title":"Autologous stem cell transplantation in elderly lymphoma patients in their 70s: outcomes and analysis","volume":"23","author":"Sun","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.jtct.2026.02.001_bib0069","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1002\/cncr.33171","article-title":"Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma","volume":"126","author":"Munshi","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2026.02.001_bib0070","article-title":"Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard-of-care therapy in relapsed\/refractory large B-cell lymphoma","volume":"41","author":"Westin","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.02.001_bib0071","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood.2023020197","article-title":"Real-world experience of CAR T-cell therapy in older patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"142","author":"Chihara","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.02.001_bib0072","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.02.001_bib0073","doi-asserted-by":"crossref","first-page":"150","DOI":"10.36401\/JIPO-21-2","article-title":"Real-world experiences of CAR T-cell therapy for large B-cell lymphoma: how similar are they to the prospective studies?","volume":"4","author":"Tang","year":"2021","journal-title":"J Immunother Precis Oncol"},{"key":"10.1016\/j.jtct.2026.02.001_bib0074","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2217\/cer.15.27","article-title":"Should criteria for inclusion in cancer clinical trials be expanded?","volume":"4","author":"Gerber","year":"2015","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.jtct.2026.02.001_bib0075","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1182\/bloodadvances.2023011184","article-title":"Estimation of eligibility for and response to CAR-T therapy in the United States","volume":"8","author":"Haslam","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.02.001_bib0076","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.02.001_bib0077","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2026.02.001_bib0078","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.02.001_bib0079","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.02.001_bib0080","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.02.001_bib0081","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2026.02.001_bib0082","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.02.001_bib0083","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jtct.2026.02.001_bib0084","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","article-title":"Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: phase 1 trial interim results","volume":"30","author":"Bagley","year":"2024","journal-title":"Nature Medicine"},{"key":"10.1016\/j.jtct.2026.02.001_bib0085","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.21037\/jtd.2020.03.118","article-title":"CAR-T cell therapy for lung cancer: a promising but challenging future","volume":"12","author":"Zhong","year":"2020","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.jtct.2026.02.001_bib0086","article-title":"Phase I study of C-CAR031, a GPC3-specific TGF\u03b2RIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC)","volume":"42","author":"Zhang","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.02.001_bib0087","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.tips.2024.07.005","article-title":"Frontiers in CAR-T cell therapy for autoimmune diseases","volume":"45","author":"Li","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jtct.2026.02.001_bib0088","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.bbmt.2013.08.002","article-title":"Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma","volume":"19","author":"Costa","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.02.001_bib0089","first-page":"1410","article-title":"The role of race, socioeconomic status, and distance traveled on the outcome of African-American patients with multiple myeloma","volume":"91","author":"Abou-Jawde","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2026.02.001_bib0090","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1200\/JCO.2008.18.2006","article-title":"Socioeconomic differences in patient survival are increasing for acute myeloid leukemia and multiple myeloma in Sweden","volume":"27","author":"Kristinsson","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.02.001_bib0091","first-page":"713","article-title":"Socioeconomic status and survival in multiple myeloma]","volume":"81","author":"Pasqualetti","year":"1990","journal-title":"Minerva Med"},{"key":"10.1016\/j.jtct.2026.02.001_bib0092","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1002\/1097-0142(19841215)54:12<3085::AID-CNCR2820541246>3.0.CO;2-Z","article-title":"Race, poverty, and survival in multiple myeloma","volume":"54","author":"Savage","year":"1984","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2026.02.001_bib0093","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.3109\/10428194.2015.1011156","article-title":"Socioeconomic status is independently associated with overall survival in patients with multiple myeloma","volume":"56","author":"Fiala","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2026.02.001_bib0094","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.bbmt.2016.03.011","article-title":"Association of socioeconomic status with outcomes of autologous hematopoietic cell transplantation for multiple myeloma","volume":"22","author":"Hong","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.02.001_bib0095","unstructured":"Garfield R, Orgera K, Damico A. The Uninsured and the ACA: A Primer - Key Facts about Health Insurance and the Uninsured amidst Changes to the Affordable Care Act, 2019. Available at:https:\/\/www.kff.org\/affordable-care-act\/the-uninsured-and-the-aca-a-primer-key-facts-about-health-insurance-and-the-uninsured-amidst-changes-to-the-affordable-care-act\/ . Accessed January 1, 2026."},{"key":"10.1016\/j.jtct.2026.02.001_bib0096","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1182\/bloodadvances.2023011996","article-title":"Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy","volume":"8","author":"Karmali","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.02.001_bib0097","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jtct.2022.04.008","article-title":"Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access","volume":"28","author":"Ahmed","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.02.001_bib0098","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1182\/blood.2022017866","article-title":"Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy","volume":"141","author":"Newman","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.02.001_bib0099","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jtct.2023.08.007","article-title":"Assessing Medicaid coverage for hematopoietic cell transplantation and chimeric antigen receptor T cell therapy: a project from the American Society for Transplantation and Cellular Therapy and the National Marrow Donor Program ACCESS Initiative","volume":"29","author":"Auletta","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.02.001_bib0100","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1093\/jnci\/djac077","article-title":"Association between Medicaid expansion under the Affordable Care Act and survival among newly diagnosed cancer patients","volume":"114","author":"Han","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jtct.2026.02.001_bib0101","unstructured":"Akash Pillai E.H., Rudowitz Robin. Samantha Artiga: KFF. Medicaid Efforts to Address Racial Health Disparities. 2024. Accessed via Medicaid Efforts to Address Racial Health Disparities | KFF. Accessed January 1, 2026 https:\/\/www.kff.org\/medicaid\/medicaid-efforts-to-address-racial-health-disparities\/"},{"key":"10.1016\/j.jtct.2026.02.001_bib0102","unstructured":"Julian Polaris B.C. Alex Dworkowitz: Access to Transformative Therapies for Medicaid Enrollees. Current Barriers and Proposed Policy Solutions, Manatt Health; 2025. Accessed January 1, 2026https:\/\/assets-us-01.kc-usercontent.com\/9fd8e81d-74db-00ef-d0b1-5d17c12fdda9\/b5e76546-0f45-4607-b0af-7a65156d91da\/Manatt%20-%20Medicaid%20CGT%20Access%20%28Feb.%202025%29.pdf"},{"key":"10.1016\/j.jtct.2026.02.001_bib0103","article-title":"Real-world analysis of barriers to timely administration of chimeric antigen receptor T cell (CAR T) therapy in diffuse large B-cell lymphoma","volume":"30","author":"Bei","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"E40","key":"10.1016\/j.jtct.2026.02.001_bib0104","first-page":"2021","article-title":"Prevalence of past-year dental visit among US adults aged 50 years or older, with selected chronic diseases","volume":"18","author":"Patel","year":"2018","journal-title":"Prev Chronic Dis"},{"issue":"vii","key":"10.1016\/j.jtct.2026.02.001_bib0105","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0011-8532(03)00038-7","article-title":"Immune suppression and considerations for dental care","volume":"47","author":"Parisi","year":"2003","journal-title":"Dent Clin North Am"},{"key":"10.1016\/j.jtct.2026.02.001_bib0106","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.14219\/jada.archive.2000.0118","article-title":"The Surgeon General's report on America's oral health: opportunities for the dental profession","volume":"131","author":"Evans","year":"2000","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.jtct.2026.02.001_bib0107","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.6026\/973206300191383","article-title":"Mobile dental clinic for oral health services to underserved rural Indian communities","volume":"19","author":"Bala","year":"2023","journal-title":"Bioinformation"},{"key":"10.1016\/j.jtct.2026.02.001_bib0108","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1007\/s12325-021-01839-y","article-title":"Travel-related economic burden of chimeric antigen receptor T cell therapy administration by site of care","volume":"38","author":"Snyder","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtct.2026.02.001_bib0109","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.bbmt.2011.08.022","article-title":"The impact of geographic proximity to transplant center on outcomes after allogeneic hematopoietic stem cell transplantation","volume":"18","author":"Abou-Nassar","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.02.001_bib0110","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1002\/cncr.33175","article-title":"Distance to treatment center is associated with survival in children and young adults with acute lymphoblastic leukemia","volume":"126","author":"Rotz","year":"2020","journal-title":"Cancer"},{"issue":"S187","key":"10.1016\/j.jtct.2026.02.001_bib0111","article-title":"Impact of socio-economic disparities and distance to bone marrow transplant center on transplantation outcomes","volume":"22","author":"Graupner","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.02.001_bib0112","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jtct.2024.04.017","article-title":"Chimeric antigen receptor T-cell access in patients with relapsed\/refractory large B-cell lymphoma: association of access with social determinants of health and travel time to treatment centers","volume":"30","author":"Ahmed","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.02.001_bib0113","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1182\/blood.2023020703","article-title":"Mitigating inequity: ethically prioritizing patients for CAR T-cell therapy","volume":"142","author":"Bell","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.02.001_bib0114","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/07347332.2025.2460060","article-title":"The patient and caregiver experience of CAR T-cell therapy: A qualitative analysis","volume":"43","author":"Reblin","year":"2025","journal-title":"J Psychosoc Oncol"},{"key":"10.1016\/j.jtct.2026.02.001_bib0115","article-title":"Quality of life and prognostic awareness in caregivers of patients receiving chimeric antigen receptor T cell therapy","volume":"30","author":"Barata","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.02.001_bib0116","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/02692163221138880","article-title":"A qualitative service evaluation of patient and caregiver experiences of CAR-T therapy: Recommendations for service development and implications for palliative care teams","volume":"37","author":"Stenson","year":"2023","journal-title":"Palliat Med"},{"key":"10.1016\/j.jtct.2026.02.001_bib0117","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/j.bbmt.2018.06.015","article-title":"Quality of life of caregivers of hematopoietic cell transplant recipients","volume":"24","author":"Jamani","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.02.001_bib0118","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1080\/10428194.2022.2074993","article-title":"Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation","volume":"63","author":"Gertz","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"23743735231202733","key":"10.1016\/j.jtct.2026.02.001_bib0119","article-title":"Experience of autologous stem cell transplant in multiple myeloma: the patient and caregiver perspective","volume":"10","author":"Hansen","year":"2023","journal-title":"J Patient Exp"},{"issue":"7","key":"10.1016\/j.jtct.2026.02.001_bib0120","doi-asserted-by":"crossref","first-page":"458.e1","DOI":"10.1016\/j.jtct.2025.04.006","article-title":"Proceedings from the Reimagining Caregiver Workshop: Addressing Caregiver Requirements for Hematopoietic Cell Transplant","volume":"31","author":"Preussler","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.02.001_bib0121","doi-asserted-by":"crossref","unstructured":"Qi CZ, Bollu V, Yang H, et al. Cost-effectiveness analysis of tisagenlecleucel for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma in the United States. Clin Ther. 43:1300-1319 e8","DOI":"10.1016\/j.clinthera.2021.06.011"},{"key":"10.1016\/j.jtct.2026.02.001_bib0122","article-title":"TACTUM: Trends in Access to Cellular Therapies in Multiple Myeloma, perspectives of treating versus referring physicians","volume":"30","author":"Atallah","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.02.001_bib0123","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jtct.2022.02.017","article-title":"Point-of-care anti-CD19 CAR T-cells for treatment of relapsed and refractory aggressive B-cell lymphoma","volume":"28","author":"Kedmi","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"101136","key":"10.1016\/j.jtct.2026.02.001_bib0124","article-title":"Access to CAR T-cell therapy: focus on diversity, equity and inclusion","volume":"63","author":"Odstrcil","year":"2024","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtct.2026.02.001_bib0125","unstructured":"ASTCT CAR-T Therapy Coding and Billing Guide, 2025. Available at: https:\/\/www.astct.org\/car-t-coding-and-billing-guide. Accessed March 17, 2026."}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726000801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726000801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:09:10Z","timestamp":1776856150000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726000801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":125,"alternative-id":["S2666636726000801"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.02.001","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breaking Access Barriers to Autologous Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy in Hematologic Malignancies\u2014an ASTCT-NMDP ACCESS Initiative","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}